231 related articles for article (PubMed ID: 33520633)
1. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.
Buitrón-González I; Aguilera-Durán G; Romo-Mancillas A
Results Chem; 2021 Jan; 3():100094. PubMed ID: 33520633
[TBL] [Abstract][Full Text] [Related]
2. Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor.
Giordano D; De Masi L; Argenio MA; Facchiano A
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440241
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
4. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
6.
Medina-Barandica J; Contreras-Puentes N; Tarón-Dunoyer A; Durán-Lengua M; Alviz-Amador A
Inform Med Unlocked; 2023; 40():101278. PubMed ID: 37305192
[TBL] [Abstract][Full Text] [Related]
7. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
8. Silybin B and Cianidanol Inhibit M
Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
[TBL] [Abstract][Full Text] [Related]
9. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
10. A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19.
Srivastava N; Garg P; Srivastava P; Seth PK
PeerJ; 2021; 9():e11171. PubMed ID: 33981493
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 liver and gastroenterology findings: An
Peiter GC; de Souza CBT; de Oliveira LM; Pagliarin LG; Dos Anjos VNF; da Silva FAF; de Melo FF; Teixeira KN
World J Hepatol; 2022 Jun; 14(6):1131-1141. PubMed ID: 35978663
[TBL] [Abstract][Full Text] [Related]
12. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.
Ahsan T; Sajib AA
Biochem Biophys Rep; 2021 Jul; 26():100982. PubMed ID: 33817352
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
14. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
16. Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.
Peng L; Tian X; Shen L; Kuang M; Li T; Tian G; Yang J; Zhou L
Front Genet; 2020; 11():577387. PubMed ID: 33193695
[TBL] [Abstract][Full Text] [Related]
17. In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity.
Maiti S; Banerjee A; Kanwar M
Vascul Pharmacol; 2021 Jun; 138():106856. PubMed ID: 33746069
[TBL] [Abstract][Full Text] [Related]
18. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
19. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
20. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
